High Dose Omeprazole in Patients With Pancreatic Cancer

Description

The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.

Conditions

Exocrine Pancreatic Cancer

Study Overview

Study Details

Study overview

The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.

A Phase 0 Study of High Dose Omeprazole in Patients With Pancreatic Cancer Planning to Undergo Surgical Therapy for Evaluating Changes of Biomarkers

High Dose Omeprazole in Patients With Pancreatic Cancer

Condition
Exocrine Pancreatic Cancer
Intervention / Treatment

-

Contacts and Locations

Oklahoma City

Stephenson Cancer Center, Oklahoma City, Oklahoma, United States, 73104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Newly diagnosed exocrine pancreatic cancer with pathology confirmed as adenocarcinoma
  • * Patient is a candidate for surgical resection of pancreatic cancer
  • * ≥ 18 years old at the time of informed consent
  • * ECOG Performance Status 0-2
  • * Patients with or without neoadjuvant chemotherapy will be eligible
  • * Ability to provide written informed consent and HIPAA authorization
  • * Women of childbearing potential definition must have a negative pregnancy test within 14 days of registration. All women (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) are considered to have childbearing potential unless they meet one of the following criteria:
  • * Prior hysterectomy or bilateral oophorectomy;
  • * Has not had menses at any time in the preceding 24 consecutive months
  • * Adequate organ function for surgical therapy
  • * Patients with pancreatic malignant tumor histologically confirmed as neuroendocrine or any other type of malignancies
  • * Positive pregnancy test, pregnant, or breastfeeding
  • * Known hypersensitivity to any component of the formulation or substituted benzimidazoles
  • * Any other clinically significant laboratory abnormality that would compromise patient safety or the outcome of the study
  • * Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study
  • * Medical condition that might affect the absorption of study medications in the opinion of the investigator.

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Oklahoma,

Ajay Jain, MD, PRINCIPAL_INVESTIGATOR, University of Oklahoma

Study Record Dates

2026-06